Perrigo Company plc reported earnings results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, the company reported sales was USD 1,109.6 million compared to USD 1,138.3 million a year ago. Net loss was USD 1,418.1 million compared to USD 44.5 million a year ago. Basic loss per share from continuing operations was USD 10.2 compared to USD 0.3 a year ago. Diluted loss per share from continuing operations was USD 10.2 compared to USD 0.3 a year ago. Basic loss per share was USD 10.22 compared to USD 0.32 a year ago. Diluted loss per share was USD 10.22 compared to USD 0.32 a year ago.
For the full year, sales was USD 4,253.1 million compared to USD 4,373.4 million a year ago. Net loss was USD 1,425.4 million compared to USD 171.8 million a year ago. Basic loss per share from continuing operations was USD 10.12 compared to USD 1.17 a year ago. Diluted loss per share from continuing operations was USD 10.12 compared to USD 1.17 a year ago. Basic loss per share was USD 10.29 compared to USD 1.25 a year ago. Diluted loss per share was USD 10.29 compared to USD 1.25 a year ago.
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
